Non-Benzodiazepine Hypnotics for Insomnia

Pharmacological Properties

Zaleplon has an ultra-short half-life of approximately 1 hour and is rapidly eliminated with minimal residual effects, making it primarily effective for sleep onset insomnia but less effective for sleep maintenance, according to the American Academy of Sleep Medicine 1
Zolpidem has a longer half-life of about 2.4 hours and a more prolonged effect, making it effective for both sleep onset and sleep maintenance insomnia, as recommended by the American Academy of Sleep Medicine 1

Zaleplon is primarily recommended for sleep onset insomnia (difficulty falling asleep) by the American Academy of Sleep Medicine 1
Zolpidem is recommended for both sleep onset and sleep maintenance insomnia (difficulty staying asleep) by the American Academy of Sleep Medicine 1

Both zaleplon and zolpidem are non-benzodiazepine hypnotics (Z-drugs) used for the short-term treatment of insomnia, as classified by the American Academy of Sleep Medicine 1, 2
Both medications are FDA-approved for short-term treatment of insomnia and are classified as controlled substances, according to the American Academy of Sleep Medicine 1, 3

The American Academy of Sleep Medicine recommends using the lowest effective dose for the shortest duration possible (typically 2-4 weeks) for both zaleplon and zolpidem 1, 2
Cognitive behavioral therapy for insomnia (CBT-I) should be considered as first-line treatment or in combination with pharmacotherapy, as suggested by the American Academy of Sleep Medicine 2

The American Academy of Sleep Medicine recommends zolpidem over zaleplon for most insomnia cases, as it treats both sleep onset and maintenance insomnia, while zaleplon only effectively addresses sleep onset difficulties 4
Zolpidem is recommended for both sleep onset and sleep maintenance insomnia, with the American Academy of Sleep Medicine providing weak recommendations for its use when pharmacological treatment is indicated 4, 5
Zaleplon shows weak objective evidence of efficacy for sleep onset insomnia that falls just below clinical significance thresholds 6
Zolpidem demonstrates clinically significant improvements in both objective sleep latency and total sleep time 5, 6

The FDA has lowered the recommended starting dose of zolpidem to 5 mg for immediate-release formulations 5
Common adverse events for zaleplon include headache, asthenia, neurasthenia, pain, fatigue, and somnolence 6
Neither medication shows significant evidence of withdrawal symptoms or rebound insomnia when used at recommended doses for the recommended treatment duration 6

Studies evaluating zaleplon for 5 weeks showed that tolerance to hypnotic effects generally did not develop during this treatment period, according to the American Academy of Sleep Medicine 7, 8